FDA Accepts Supplement for Sonazine (Chlorpromazine Hydrochloride)
The FDA has accepted a supplemental application for Sonazine, a formulation of Chlorpromazine Hydrochloride, by Saptalis Pharmaceuticals.
Asset / Drug
Drug and asset intelligence for Sonazine with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.